"Globally, we are now seeing a plateauing in the number of #COVID19 cases and deaths, with declines in most regions”, says @DrTedros at @WHO presser. "But it’s an unacceptably high plateau, with more than 5.4 million reported #covid19 cases and almost 90.000 deaths last week."
@DrTedros@WHO “We've been here before”, says @drtedros. “Over the past year, many countries have experienced a declining trend in cases and deaths, relaxing public health and social measures too quickly, and individuals have laid down their guard, only for those hard won gains to be lost."
@DrTedros@WHO "We are still in a perilous situation”, says @DrTedros.
"The spread of variants, increased social mixing, the relaxation of public health and social measures and inequitable vaccination, are all driving transmission."
@DrTedros@WHO “The shocking global disparity in access to vaccines remains one of the biggest risks to ending the pandemic”, says @drtedros. “Low- and lower-middle income countries account for 47% of the world’s population but have received just 17% of the world’s vaccines."
@DrTedros@WHO "My message to leaders is use every tool at your disposal to drive transmission down right now”, says @DrTedros.
Even where immunization is high, "public health capacities must be strengthened to prepare for the possibility of vaccine-evading variants, and for future emergencies"
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The most comprehensive review of how the world responded to #covid19 and how to prevent the next pandemic was published today.
It will likely be the basis of discussions in coming months and years and so I read it for you.
Who wrote the report?
This is the Independent Panel for Pandemic Preparedness and Response (IPPPR), established last year in response to a resolution of the World Health Assembly.
It consists of 13 members led by @HelenClarkNZ and @MaEllenSirleaf.
@HelenClarkNZ@MaEllenSirleaf (To be completely transparent:
I was actually interviewed by this panel in February but only about the communication aspects of the pandemic. I have no other involvement with this report or the panel.)
@GretchenVogel1@Sciencenorwayno I have made the point again and again that his is about context.
In this case on top of low infection rates (see page 9):
- mRNA vaccines are becoming available faster in Norway
- 2nd dose of mRNA now to be given after 12 weeks, so more people will get first dose faster.
@GretchenVogel1@Sciencenorwayno If the context changes, decision may too:
Recommendation is "based on the level of knowledge we have at present… Changes in infection rates, new virus mutants, unforeseen problems with vaccine deliveries and new information about side effects could lead to other conclusions"
“I know that this is not a politically easy thing to do. So I very much appreciate the leadership of the United States", says @DrTedros at @WHO presser on #covid19 about US support for #TRIPSwaiver “We urge other countries to follow their example.”
@DrTedros@WHO "We are in an unprecedented crisis that requires unprecedented action”, says @drtedros.
“The World Trade Organization provisions for IP waivers were designed precisely for a situation like this.
If we don't use them now, then when?"
@DrTedros@WHO This is important news:
"This afternoon, WHO gave emergency use listing to Sinopharm Beijing's #COVID19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality."
UK’s Joint Committee on Vaccination and Immunisation is now advising healthy adults younger than 40 “to receive an alternative to the Oxford/AstraZeneca vaccine – where available and only if this does not cause substantial delays in being vaccinated”.
This is based on the fact that “the chances of a younger person becoming seriously ill with #COVID19 get smaller as infection rates increasingly come under control in the UK”. @GretchenVogel1 and explored these trade-offs in risk and benefit here:
@GretchenVogel1 UK's regulator, the MHRA:
"The balance of benefits and risks is very favourable for older people but is more finely balanced for younger people and we advise that this evolving evidence should be taken into account when considering the use of the vaccine” gov.uk/government/new…
So where are we on the rare clotting disorder linked to AZ and J&J shots? What do we know? How do risks and benefits compare? What does it mean long-term and around the world? @GretchenVogel1 and I tried to answer some questions, thread to come in a bit.
First off:
This is complex and I‘m tired of people pretending it‘s all obvious.
So a few general points about the decisions that have to be made here:
They are
- local, but with global implications
- based on imperfect data in an evolving pandemic
- about individual decisions as well as population-level effects (and these two things can point in opposite directions)
In the US the Advisory Committee on Immunization Practices (ACIP) is meeting at the moment to discuss data on the rare clotting disorders seen after immunization with J&J’s #covid19 vaccine and to make recommendations on future use of the vaccine.
I’ll tweet along a bit.
Outcomes from the rare clotting disorders are likely to improve from "recognition among physicians also recognition in the public that if you develop a severe headache, severe abdominal pain that you really need to see your doctor", says @mstreif1.
@mstreif1 As of 21 April, 15 confirmed cases of the rare clotting disorder (here called TTS, Thrombosis with Thrombocytopenia Syndrome) after about 8 million vaccinations with J&J’s #covid19 vaccine, says @CDCgov's Tom Shimabukuro